Discontinued drugs in 2006: cardiovascular drugs translational medicine perspective.
This perspective on discontinued cardiovascular drugs is the first in a series of papers on drugs dropped from clinical development in 2006. The compounds described in this perspective have been removed from development in various stages and for different reasons. This paper hereby provides a translational medicine perspective on these compounds based on information available through the Pharmaprojects pipeline database. In particular, potential gaps in the pipeline, due to a lack of biomarkers and translational medicine perspectives are emphasized.
Feuerstein
Giora Z
GZ
Discovery Translational Medicine, Wyeth Research, Collegeville, PA 19426, USA. feuersg@wyeth.com
Ruffolo
Robert R
RR
D000818:Animals; D015415:Biomarkers / Q000032:analysis; D002317:Cardiovascular Agents / Q000009:adverse effects* / Q000145:classification / Q000592:standards*; D017277:Drug Approval / Q000379:methods; D004345:Drug Industry / Q000379:methods* / Q000592:standards* / Q000639:trends; D015507:Drugs, Investigational / Q000009:adverse effects / Q000145:classification / Q000592:standards; D006801:Humans
D015415:Biomarkers; D002317:Cardiovascular Agents; D015507:Drugs, Investigational